Treatment and Outcomes of DLBCL After Progression on Polatuzumab Vedotin-based Combination Therapy

Inclusion Criteria

• •Patients diagnosed with DLBCL
• •Age ≥18 years
• •Prior treatment with a polatuzumab vedotin (pola)-containing regimen and confirmed disease progression (refractory/relapsed) after this therapy.
• •Availability of complete electronic medical records and ability to be contacted via telephone.
• •Full understanding of the study, voluntary participation, and willingness to sign the informed consent form.